BREAST CANCER

Virginia Kaklamani, MD, DSc, discusses the impact of the Phase III EMERALD trial results on the treatment landscape of HR+/HER2-low metastatic breast cancer, emphasizing the importance of selecting optimal drug combinations while minimizing toxicity profiles.

Virginia Kaklamani, MD, DSc, presents a case of metastatic breast cancer, initially responsive to first-line aromatase and CDK4/6 inhibitors, that progressed after 32 months. She explores using biomarker testing to identify ESR1 and other actionable mutations potentially causing endocrine resistance, guiding the transition to second-line therapy.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

In the first article in a 2-part series, William J. Gradishar, MD, discusses the importance of elacestrant for treating patients with ESR1 positive metastatic breast cancer.

Samilia Obeng-Gyasi, MD, MPH, delved into the background and findings of this study assessing the correlation between neighborhood opportunity, allostatic load, and all-cause mortality among patients with breast cancer.

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.

In an interview for Triple-Negative Breast Cancer Awareness Day, Daniel Carlson, DO, delved into the complexities of the disease, highlighting the current space and future possibilities.

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Allina Health Cancer Institute and Astrin Biosciences are jointly integrating AI to improve the assessment of cancer cells in blood samples, beginning with breast cancer, which faces challenges with mammogram imaging and demands innovative solutions.

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Following a favorable independent data monitoring committee review, the phase 3 PRESERVE 2 trial of trilaciclib in the first-line for patients with metastatic triple negative breast cancer treatment will move forward.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joyce O'Shaughnessy, MD, reviewed the current state of CDK4/6 inhibitor therapy for patients with advanced estrogen-receptor positive breast cancer.

A trial investigating REM-001 therapy in cutaneous metastatic breast cancer has been initiated.

In the second article of a 2-part series, Komal Jhaveri, MD, leads a discussion on the considerations physicians must have when looking to give elacestrant to patients with estrogen receptor–positive, HER2 negative metastatic breast cancer.

Chirag Shah, MD, discussed findings from the PREDICT study which looked at DCISionRT testing for patients with ductal carcinoma in situ breast cancer.

Goserelin is now included in the NCCN Breast Cancer Panel guidelines at 2 dosing schedules for ovarian function suppression in Version 1.2024.

If approved, vepdegestrant could provide a valuable new treatment option for patients with ER+/HER2- breast cancer who have progressed after receiving endocrine therapy.

Virginia Kaklamani, MD, DSc, explains that key unmet needs in HR+/HER2- metastatic breast cancer include overcoming diverse mechanisms of endocrine resistance with genomic profiling and new agents like oral SERDs while managing side effects.

Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.

The FDA has decided to re-evaluate the ProSense System as a minimally invasive treatment option for patients with early-stage, low-risk breast cancer.

Virginia Kaklamani, MD, DSc, details that disease burden and location of metastases in patients with HR+/HER2- metastatic breast cancer guide approaches to management, with visceral metastases indicating potentially faster progression and more concerning symptoms.

Virginia Kaklamani, MD, DSc, shares that in deciding second-line therapy for metastatic breast cancer after CDK4/6 inhibitors, endocrine sensitivity guides the choice between treatments based on ESR1/PIK3CA mutations and safety profiles with/without fulvestrant injections.

Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.

Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.

Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.